Analytical Data
-
Gene name
VEGFR-2
-
简介
VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Rhesus macaque (HEK293, His) is the recombinant Rhesus Macaque-derived VEGFR-2 protein, expressed by HEK293 , with C-His labeled tag.
- Application
-
Alternative Names
KDR; CD309; FLK1; VEGFR; VEGFR2
-
Species
Rhesus Macaque
-
Source
HEK293
-
Tag
C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
F7E313
-
Expression Region
A20-E764
-
Protein Length
Partial
-
Molecular Weight
115-145 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Vascular endothelial growth factor receptor 2 (VEGFR-2) is a key receptor involved in the process of angiogenesis, which is the formation of new blood vessels from pre-existing ones. This protein is predominantly expressed in endothelial cells and plays a critical role in regulating vascular permeability, blood vessel formation, and the response to hypoxia. Dysregulation of VEGFR-2 signaling is associated with various diseases, including cancer, where tumor growth and metastasis often depend on the formation of new blood vessels to supply nutrients and oxygen. The study of VEGFR-2 recombinant proteins has gained significant attention as they offer potential therapeutic avenues for anti-angiogenic strategies. Researchers are particularly interested in understanding the structural and functional properties of VEGFR-2, which can lead to the development of novel inhibitors that can block its activity. Such efforts may provide a means to inhibit tumor growth and reduce the spread of cancer, making VEGFR-2 a valuable target in the design of cancer therapies. The development of VEGFR-2 recombinant proteins also facilitates the exploration of its role in vascular biology and other physiological processes, ultimately contributing to the advancement of therapeutic options for related diseases.
